Bayer (ETR:BAYN) target price raised to 118.00EUR, reported today by equinet AG
- Updated: September 15, 2016
equinet AG raised the price target of Bayer (ETR:BAYN) to 118EUR, reporting a possible upside of 0.29%.
Previously on 8/29/2016, Citigroup Corp. released a statement about Bayer(ETR:BAYN) upped the target price from 0.00EUR to 120.00EUR. At the time, this indicated a possible upside of 0.24%.
Just yesterday Bayer (ETR:BAYN) traded 7.14% lower at 91.44EUR. BAYN’s 50-day average is 0.04EUR and its 200-day moving average is 0.03EUR. The last close is up 1.82% relative to the 200-day moving average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same time period. 10,000 shares of Bayer traded, up from ann avg. trading volume of 211.
Recent Performance Graphic:
Bayer has a one-year low of 0.03EUR and a one-year high of 0.04EUR . BAYN’s market capitalization is currently 0.0 EUR.
About Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.